

Top 10 M&A Deals in Healthcare & Life Sciences in 2022

2022 saw a slight uptick in M&A activity in the Healthcare and Life Sciences space, leading to stronger synergies in the healthcare system

AHMEDABAD, GUJARAT, INDIA, March 14, 2023 /EINPresswire.com/ -- Overall appetite and activity in terms of M&A deals has reduced in the healthcare sector in 2022, with decrease in the number of deals but slight increase in the total deal value as compared to 2021. This was driven by a greater

number of high value deals leading to an increase in the average deal size. Healthcare investors were largely focused on acquiring companies with innovative technologies, concentrating on patient-accessibility, which could complement their capabilities in the current market which was broadly unstable, due to a series of macroeconomic challenges.


“

2023 is expected to be a year with significant M&A activity fueled by loss of patent exclusivity, competition from generics and biosimilars, breakthrough technology and increased patient awareness”

Dr. Purav Gandhi

focus, impact, and others.

Pharma & Biotech accounted for 40% of the deals, with the Amgen – Horizon Therapeutics \$28.3 B mega deal topping the list, followed by two strategic acquisitions made by Pfizer i.e., of Biohaven and Global Blood Therapeutics and Bristol Myers Squibb’s acquisition of Turning Point.



“[Top 10 M&A Deals in Healthcare & Lifesciences in 2022](#)”, a research report by [Healthark Insights](#) includes the top deals in the healthcare and life science sector during the year. The research is based on an evaluation of 200+ deals across Pharma & Biotech, MedTech, Health Technology, Providers, Primary Care and Payer sectors. Further, each deal category was assigned a weightage and a ranking metric was used basis the impact on the broader healthcare ecosystem. The top 10 transactions were determined based on factors such as deal size, region of

Oncology, Rare Disease, Hematology, Neurology and Cardiovascular were the major focus areas for Pharmaceutical M&As. The looming patent expirations and severe pressure to strengthen the R&D pipeline drove big pharma to make big strategic buyouts in this space.

Home health and hospice transactions covered a significant share in the total valuation, driven by two megadeals – CVS' acquisition of Signify Health for \$8 B and Optum's acquisition of LHC Group for \$6 B. These acquisitions were on the similar lines as initiated by Humana's purchase of Kindred Home in 2021. These deals signify rising the interest among payers to operate healthcare provider companies, especially those that are well-positioned to participate in value-based, risk-bearing payment models.

Stakeholders across healthcare

industry started expanding or penetrating primary care practices. This is evident by Walgreens backed VillageMD's \$8.9 B acquisition of Summit Health. And even Health tech giant Amazon joined this spree with the acquisition of One Medical for \$3.9 B, vocalizing its ambitions of penetrating deep into the primary healthcare services.

Moving forward, 2023 is expected to be a year when significant deals are executed, despite forecasts of cautious private equity investing and a moderate recession. The increase in M&A activity will be fueled by loss of patent exclusivity, competition from generics and biosimilars, growing gene therapy pipeline, breakthroughs in digital technologies and increased patient awareness and requirements.

To get an in-depth insight on the top 10 healthcare and life science M&A deals, please visit [Healthark Insights website](#).

About Healthark Insights Top 10 Research Report Series

Healthark Insights annually tracks the top events and trends in the healthcare and life sciences industry, and publishes [five reports](#) at the end of each year summarizing the top 10 trends in healthcare industry, life sciences industry, health tech, the top 10 innovations and top 10



Top 10 Healthcare M&A deals in 2022 - Part I



Top 10 Healthcare M&A deals in 2022 - Part II

mergers & acquisitions, with an objective of summarizing the key events and industry shaping forces during the previous year, and shares a view-point on how the sector will evolve in the coming year.

About Healthark Insights

Healthark Insights is a global management consulting firm developed by a team of experts from diverse fields such as consulting, pharma, medicine, medical devices, digital health, public health, and management with a common vision to cater to the healthcare and life sciences industry, along with a relentless focus on delivering executable solutions.

Healthark Insights team helps customers make critical decisions every day through expertise that combines deep domain knowledge, rigorous research, and analysis, understanding of markets, technology, and experience. With the right experience and expertise, the team not only provides insights but also works closely with clients to execute the strategy that they have helped develop.

Purav Gandhi

Healthark Wellness Solutions LLP

+91 91600 01292

[email us here](#)

Visit us on social media:

[Twitter](#)

[LinkedIn](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/622044770>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.